In a report released today, Vamil Divan from Mizuho Securities reiterated a Buy rating on Alkermes (ALKS), with a price target of $28.00. The company’s shares closed last Tuesday at $23.20, close to its 52-week high of $23.32.
According to TipRanks.com, Divan is a 2-star analyst with an average return of 0.3% and a 48.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Alkermes is a Hold with an average price target of $22.17.
See today’s analyst top recommended stocks >>
Alkermes’ market cap is currently $3.67B and has a P/E ratio of -48.50. The company has a Price to Book ratio of 4.08.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALKS in relation to earlier this year. Last month, Wendy Dixon, a Director at ALKS bought 35,000 shares for a total of $441,700.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
